M 1885 Clevudine |
|
| Click here for Typical Certificate of Analysis | |
| (L-FMAU; 1-(2-Deoxy-2-fluoro-ß-L-arabinofuranosyl)-5-methyluracil) | |
|
MORpure™ HPLC purified, Delivered ≥ 98% pure with dated HPLC UV chromatogram |
|
| Solid | |
| Screw cap v-vial - shipped on dry ice |
1 mg $215 |
| M.W. 260.22 | |
| This material is pharmaceutically unrefined, and not intended for use in humans, clinical diagnosis, or data derived from its use to support regulatory filings. | |
MG 118 Clevudine, [2-13C-1,3-15N2, 99 atom % 13C, 99 atom % 15N2]- |
|
|
(L-FMAU, [2-13C-1,3-15N2,
99 atom % 13C, 99 atom % 15N2]-; 1-(2-Deoxy-2-fluoro-ß-L-arabinofuranosyl)-5-methyluracil, [2-13C-1,3-15N2, 99 atom % 13C, 99 atom % 15N2]-) |
|
|
MORpure™ HPLC purified, Delivered ≥ 98% pure with dated HPLC UV chromatogram |
|
| Solid |
1 mg $615 |
| Screw cap v-vial - shipped on dry ice |
5 mg $1930 |
M.W. 263.2  | |
| This material is pharmaceutically unrefined, and not intended for use in humans, clinical diagnosis, or data derived from its use to support regulatory filings. | |
MT 1726 Clevudine, [5'-3H]- |
|
| Click here for Typical Certificate of Analysis | |
|
(L-FMAU, [5'-3H]-; 1-(2-Deoxy-2-fluoro-ß-L-arabinofuranosyl)-5-methyluracil, [5'-3H]-) |
|
|
MORpure™HPLC purified, Delivered ≥ 97% pure with dated HPLC radiochromatogram |
|
| Ethanol:water (1:1) solution, 1 mCi/ml | |
| > 10 Ci(0.37 TBq)/mmol |
250 µCi (9.25 MBq) $1970 |
| NextGen V-Vial - shipped on dry ice |
1 mCi (37 MBq) $4190 |
| M.W. 260.22 | |
| This material is pharmaceutically unrefined, and not intended for use in humans, clinical diagnosis, or data derived from its use to support regulatory filings. | |
M 1878 1-(2-Deoxy-2-fluoro-ß-D-arabinofuranosyl)-5-methyluracil |
|
| (D-FMAU) | |
|
MORpure™ HPLC purified, Delivered ≥ 98% pure with dated HPLC UV chromatogram |
|
| Solid | |
| Screw cap v-vial - shipped on dry ice |
1 mg $215 |
| M.W. 260.22 | |
| This material is pharmaceutically unrefined, and not intended for use in humans, clinical diagnosis, or data derived from its use to support regulatory filings. | |
MT 1769 1-(2-Deoxy-2-fluoro-ß-D-arabinofuranosyl)-5-methyluracil, [methyl-3H(N)]- |
|
| Click here for Typical Certificate of Analysis | |
|
MORpure™ HPLC purified, Delivered ≥ 97% pure with dated HPLC radiochromatogram |
|
| Ethanol:water (1:1) solution, 1 mCi/ml | |
| > 0.4 Ci(14.8 GBq)/mmol | 50 μCi (1.85 MBq) $1160 |
| NextGen V-Vial - shipped on dry ice | 250 μCi (9.25 MBq) $1970 |
| M.W. 260.22 | |
| This material is pharmaceutically unrefined, and not intended for use in humans, clinical diagnosis, or data derived from its use to support regulatory filings. | |
MC 2041 1-(2-Deoxy-2-fluoro-ß-D-arabinofuranosyl)-5-methyluracil, [2-14C]- |
|
|
MORpure™ HPLC purified, Delivered ≥ 98% pure with dated HPLC radiochromatogram |
|
| Ethanol:water (1:1) solution, 100 µCi/ml | |
| > 50 mCi(1.85 GBq)/mmol |
10 µCi (370 kBq) $1240 |
| NextGen V-Vial - shipped on dry ice |
50 µCi (1.85 MBq) $3970 |
| M.W. 260.22 | |
| This material is pharmaceutically unrefined, and not intended for use in humans, clinical diagnosis, or data derived from its use to support regulatory filings. | |